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Abstract
Purpose—To report a case of sequential bilateral central retinal vein occlusions in a cystic
fibrosis patient with hyperhomocysteinemia and hypergamma-globulinemia over 6 years of follow
up.
Methods—Observational case report of one patient.
Results—A 31 year-old male with a history of cystic fibrosis presented with a central retinal vein
occlusion (CRVO) in his left eye, followed by a CRVO in his right eye 4 years later. His medical
workup was significant for elevated levels of homocysteine and gamma-globulins, which
coincided with initiation of intravenous immunoglobulin (IVIG) proceeding his second CRVO.
Conclusions—We describe a case of sequential bilateral central retinal vein occlusions in a
cystic fibrosis patient with hyperhomocysteinemia and hypergamma-globulinemia over 6 years of
follow up and discuss the important role of these risk factors in retinal venous occlusive disease.
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We report a case of a 31 year-old male with cystic fibrosis (CF) who presented with a
central retinal vein occlusion (CRVO) and 4 years later developed a contralateral CRVO.
Workup for an underlying cause revealed elevated levels of homocysteine and gammaglobulins.

Case Report
A 31-year-old male with a history of CF presented in May 2004 complaining of blurry spots
and floaters in his left eye for 3 weeks. His past medical history included extensive
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complications from cystic fibrosis: bronchiectasis, chronic pulmonary pseudomonas
infections, allergic bronchopulmonary aspergillosis, bronchiolitis obliterans syndrome,
Barrett’s esophagitis, Clostridium difficile colitis, paroxysmal supraventricular tachycardia,
hypertension, and neuropathy. His past surgical history was also extensive, and of major
significance he underwent a double lung transplant in July 2004 and a repeat double lung
transplant in June 2007. He was on numerous medications including: tacrolimus,
prednisone, mycophenolate, esomeprazole, pancrelipase, duloxetine, azithromycin, bactrim,
valacyclovir, losartan, amlodipine, carvedilol, and gabapentin.
The day of presentation to our service, his best-corrected visual acuity was 20/20 OD and
20/40−1 OS. Intraocular pressures were 12 mm Hg OU by applanation tonometry. Anterior
segments were normal bilaterally. Dilated funduscopic examination was normal OD and
showed signs of papillophlebitis OS.
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When he returned 3 days later for follow up, visual acuity worsened to counting fingers and
the exam was consistent with a CRVO (figure 1). Fluorescein angiography confirmed the
diagnosis (figure 2). A workup to find an underlying etiology showed unremarkable
hematologic studies (CBC, coagulation profile, protein C and S activity, anti-cardiolipin
antibodies, lupus anticoagulant, and anti-thrombin III). FTA-ABS, RPR, ANA, and
hemoglobin electrophoresis were negative. Carotid dopplers, cardiac echography, and CT of
the orbits were normal. A homocysteine level was not evaluated. The patient did not have
any indwelling catheters, was afebrile and did not have symptoms or signs of infection.
At one-month follow up, the macula remained edematous and an intravitreal triamcinolone
injection was administered. By 4 months, the macula was much less edematous with
decreased exudation and hemorrhages (figure 3). Visual acuity was 20/100 and OCT
confirmed decreased macular edema (figure 4).
By 6 months, visual acuity dropped to 20/200 and the macular edema worsened. He then
received a second intravitreal triamcinolone injection. Three weeks later, the macular edema
improved but gonioscopy showed neovascularization of the angle. He underwent prompt
panretinal laser photocoagulation and the neovascularization regressed. At the 10-month
follow up visit, the macular edema worsened although visual acuity was stable at 20/200.
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The patient was subsequently lost to follow up over the next 3.5 years. He returned in
September 2009 complaining of blurry vision in his previously unaffected right eye. Visual
acuity was 20/30 OD with an intraocular pressure of 10 mm Hg. Anterior segment
examination was normal. Dilated fundus examination revealed a CRVO OD, confirmed with
fluorescein angiography (figure 5). Optical coherence tomography showed macular edema
OU, worse in the right eye, and retinal atrophy OS (figure 6).
The previous laboratory tests were repeated with the addition of Factor V Leiden and
prothrombin gene mutation, all which were unremarkable. The patient had a history of
treated hypertension, but review of his medical record over a 6-year period showed he was
relatively well controlled (figure 7). He had no indwelling catheters, was afebrile and did not
have symptoms or signs of infection. His lipid profile over this period showed normal
cholesterol and LDL levels, but elevated triglycerides (figure 7). His homocysteine level
was elevated at 24.7 µM/L (lab reference range 5.6–13.4 µM/L). A serum protein
electrophoresis showed presence of cryoglobulins and an elevated gamma fraction. Review
of the medical record indicated that he started intravenous immunoglobulin (IVIG) 9 months
prior to the second CRVO and there was a sharp rise in serum IgG preceding the second
CRVO (figure 7).
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His hyperhomocysteinemia was due to dietary causes, and he was treated with folate and
vitamin B12. Over the course of the next 16 months, the patient received 10 bevacizumab
injections to his right eye with visual acuity improving to 20/20 at the best point, but
declining to 20/150 with accumulation of the macular edema. Five weeks after his last visit,
he was admitted to the intensive care unit for pseudomonas pneumonia. His clinical course
worsened and he expired a few weeks later due to advanced chronic lung rejection and
respiratory infection.

Discussion
This case report illustrates an unusual presentation of sequential bilateral CRVOs in a cystic
fibrosis patient within a 4-year period. To our knowledge, there is no known association
between cystic fibrosis and CRVO. Though our patient did have a history of hypertension,
review of his medical record indicated that his hypertension was reasonably well controlled.
His workup revealed two possible etiologies for the second CRVO: hyperhomocysteinemia
and hypergamma-globulinemia.
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Hyperhomocysteinemia is a well-known independent risk factor for vascular disease.
Researchers have documented that patients with coronary artery disease (CAD) have
elevated levels of homocysteine and that the relative risk of CAD in patients with
hyperhomocysteinemia may be 24 times that of controls.1 Further work led to the findings
that hyperhomocysteinemia confers an independent risk factor for myocardial infarcation.2
Investigators have found that hyperhomocysteinemia may confer up to a 3.4 fold risk of
venous thrombosis.3
Associations between hyperhomocysteinemia and retinal vascular occlusion have been
mostly limited to case reports or small series.4–6 In 2000, Vine published a case-control
series of 74 patients who had unilateral or bilateral CRVOs.7 He found that the odds ratio for
a CRVO in subjects with a homocysteine level greater than the 95th percentile compared
with those less than this percentile was 6.53 (p=0.003). Most cases of elevated homocysteine
can be readily reversed with folic acid supplementations, stressing the importance of testing.
Moreover, studies in children with CF have found that choline phosphoglyceride excretion is
increased and is associated with decreased plasma methionine and increased homocysteine
and S-adenosylhomocysteine.8,9
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The association between hypergamma-globulinemia and CRVO has not been well
established in the literature. Oh et al. reported a case of a 17-year-old male with acute
lymphocytic leukemia who developed bilateral CRVOs in association with high dose
IVIG.10 Although our patient was not treated with IVIG prior to the first CRVO, he
developed a contralateral CRVO within 9 months of initiating IVIG. Review of his medical
record showed a sharp rise in gamma-globulin levels preceding the second CRVO. While
we cannot establish cause and effect based on this single observation, we refer the reader to
a manufacturer’s product label (GAMMAGARD, Baxter Healthcare Corporation, Deerfield,
Il) which states “thrombotic events have been reported in association with IVIG” and that
“baseline assessment of blood viscosity should be considered in patients at risk for
hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high
triaglycerols (triglycerides), or monoclonal gammapathies.” We note that our patient had
cyroglobulins and high levels of triglycerides.
In summary, we report an unusual case of a 31 year-old male with CF who developed
sequential bilateral CRVOs within 4 years. His workup revealed hyperhomocysteinemia, an
important etiology for CRVO, and hypergamma-globulinemia, a possibly important etiology
for CRVO that has not been well established. Homocysteine levels may be increased in CF
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patients due to alterations in the methionine-homocysteine cycle and therefore homocysteine
serves as an important risk factor for thrombosis in these patients. The compounding of
hyperhomocysteinemia with hypergamma-globulinemia may have further increased the risk
of thrombosis in our patient and emphasizes the importance of both risk factors.
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Figure 1.

Color photographs from presentation showing (a) normal fundus OD and (b) CRVO OS.
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Figure 2.

Fluorescein angiogram at presentation showing (a) CRVO OS and (b) normal angiogram
OD.
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Figure 3.

Color photograph at 4 months follow up showing less macular edema, exudates, and
hemorrhages.
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Figure 4.

Time domain OCT (a) retinal thickness map and (b) horizontal line scan through the fovea
OS showing decreased macular edema at 4 months follow up.
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(a) Fundus photo OD at the time of presentation of second CRVO. Fluorescein angiogram
demonstrating (b) new CRVO OD and (c) old CRVO OS.

Retin Cases Brief Rep. Author manuscript; available in PMC 2014 January 06.

Gelman et al.

Page 14

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 6.

SD-OCT images obtained at the time of presentation of the second CRVO. Horizontal line
scan through fovea (a) OD and (b) OS showing cystic edema OU and retinal atrophy OS.
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Figure 7.

Plotted as a function of time are the patient’s: (a) systolic and diastolic blood pressures, (b)
cholesterol, LDL, and triglyceride levels and (c) serum IgG levels. Mean levels over the
time periods are indicated by horizontal dashed reference lines. Of significance, triglyceride
levels were elevated. Intravenous immunoglobulin (IVIG) was initiated in January 2008 and
serum IgG levels sharply increased preceding the second CRVO in September 2008.
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